- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 18.03. | Marvel Biosciences Corp: Marvel Biosciences obtains U.S. patent for drug MB-204 | 1 | Stockwatch | ||
| 18.03. | Marvel Biosciences Corp.: Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 | 174 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 04.03. | Marvel Biosciences Corp.: Marvel Biosciences Sponsors Scientific Meeting on Purines | 180 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 19.02. | Marvel Biosciences Corp: Marvel Biosciences obtains financing to develop drug | 2 | Stockwatch | ||
| 18.02. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 356 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 18.02. | Marvel Biosciences Corp.: Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders | 125 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the... ► Artikel lesen | |
| 04.02. | Marvel Biosciences Corp: Marvel Biosciences receives Japanese patent for MB-204 | 1 | Stockwatch | ||
| 03.02. | Marvel Biosciences Corp.: Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 | 322 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or... ► Artikel lesen | |
| 22.12.25 | Toronto Stock Exchange: Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite | 410 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 22, 2025) - Rod Matheson, Chief Executive Officer, and Mark Williams, Chief Strategy Officer, from Marvel Biosciences Corp. (the "Company") (TSXV: MRVL)... ► Artikel lesen | |
| 11.11.25 | Marvel Biosciences Corp: Marvel Biosciences grants 35,697 deferred share units | 2 | Stockwatch | ||
| 10.11.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 436 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 03.10.25 | Marvel Biosciences Corp: Marvel Biosciences accelerates expiry of warrants | 3 | Stockwatch | ||
| 03.10.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Acceleration of Warrant Expiry Date | 471 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is... ► Artikel lesen | |
| 18.08.25 | Marvel Biosciences Corp.: Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204 | 522 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 12.08.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 599 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 13.05.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Private Placement | 715 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 02.05.25 | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Second Tranche of Private Placement | 403 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased... ► Artikel lesen | |
| 30.04.25 | Marvel Biosciences Corp.: Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment | 256 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 16.04.25 | Marvel Biosciences Corp.: Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting | 214 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased... ► Artikel lesen | |
| 14.04.25 | Marvel Biosciences Corp.: Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference | 228 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | -16,51 % | ADMA Biologics drops amid short report from Culper Research | ||
| QIAGEN | 34,465 | 0,00 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,640 | +2,82 % | Why Edgewise Therapeutics Stock Topped the Market on Tuesday | ||
| KINIKSA PHARMACEUTICALS | 44,940 | -2,33 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,570 | -3,05 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,66 | +0,05 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| APOGEE THERAPEUTICS | 72,98 | -7,81 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,060 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 12,330 | -0,56 % | Stifel reiterates Buy on Contineum stock, keeps $29 price target | ||
| EVOTEC | 4,119 | 0,00 % | Welche Aktie jetzt kaufen? Evotec, Nel und Lahontan Gold. | Was ist denn da bei Nel los? Innerhalb weniger Tage hat die einstige Wasserstoffhoffnung über 20 % an Wert gewonnen. Der kurzfristige Abwärtstrend wurde verlassen. Doch Analysten sehen keine Trendwende.... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,480 | +2,74 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| ERASCA | 14,645 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| LENZ THERAPEUTICS | 9,010 | -18,09 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Launched VIZZ- (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 5,500 | -0,36 % | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen |
Das Unternehmen MARVEL BIOSCIENCES CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.